Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 Extended Release (ER)
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2016
At a glance
- Drugs Viloxazine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Registrational
- Sponsors Supernus Pharmaceuticals
- 02 Aug 2016 According to a Supernus Pharmaceuticals media release, enrollment has reach 84% of the planned patient number in this trial.
- 15 Apr 2016 New trial record
- 13 Apr 2016 Status changed from not yet recruiting to recruiting.